Checkmate Pharmaceuticals (CMPI) IPO prices at $15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Bel Fuse acquires dataMate ethernet business for $16 million
- Fed: Nine Of 18 FOMC Participants Pencil In 2026 Rate Hike
Checkmate Pharmaceuticals Announces Pricing of Initial Public Offering
August 6, 2020 9:17 PM EDTCAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share. All of the shares are being offered by Checkmate. Checkmates common stock is expected to begin trading on the Nasdaq Global Market under the ticker symbol CMPI on August 7, 2020. The gross proceeds of the offering, before deducting underwriting... More
